Publication
Pyrimidyn‐Based Dynamin Inhibitors as Novel Cytotoxic Agents
Publisher:
Wiley
Date:
10-11-2022
DOI:
10.1002/CMDC.202100560
Abstract: Five focused libraries of pyrimidine‐based dynamin GTPase inhibitors, in total 69 compounds were synthesised, and their dynamin inhibition and broad‐spectrum cytotoxicity examined. Dynamin plays a crucial role in mitosis, and as such inhibition of dynamin was expected to broadly correlate with the observed cytotoxicity. The pyrimidines synthesised ranged from mono‐substituted to trisubstituted. The highest levels of dynamin inhibition were noted with di‐ and tri‐ substituted pyrimidines, especially those with pendent amino alkyl chains. Short chains and simple heterocyclic rings reduced dynamin activity. There were three levels of dynamin activity noted: 1–10, 10–25 and 25–60 μM. Screening of these compounds in a panel of cancer cell lines: SW480 (colon), HT29 (colon), SMA (spontaneous murine astrocytoma), MCF‐7 (breast), BE2‐C (glioblastoma), SJ‐G2 (neuroblastoma), MIA (pancreas), A2780 (ovarian), A431 (skin), H460 (lung), U87 (glioblastoma) and DU145 (prostate) cell lines reveal a good correlation between the observed dynamin inhibition and the observed cytotoxicity. The most active analogues ( 31 a , b ) developed returned average GI 50 values of 1.0 and 0.78 μM across the twelve cell lines examined. These active analogues were: N 2 ‐(3‐dimethylaminopropyl)‐ N 4 ‐dodecyl‐6‐methylpyrimidine‐2,4‐diamine ( 31 a ) and N 4 ‐(3‐dimethylaminopropyl)‐ N 2 ‐dodecyl‐6‐methylpyrimidine‐2,4‐diamine ( 31 b ).